# A Study of Niraparib in Patients With Relapsed Ovarian Cancer

> **NCT04392102** · PHASE2 · COMPLETED · sponsor: **Zai Lab (Shanghai) Co., Ltd.** · enrollment: 15 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** ZL-2306(Niraparib）

## Key facts

- **NCT ID:** NCT04392102
- **Lead sponsor:** Zai Lab (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-04
- **Primary completion:** 2021-04-08
- **Final completion:** 2022-08-11
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04392102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04392102, "A Study of Niraparib in Patients With Relapsed Ovarian Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04392102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*